LP
ALNY icon

LMR Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

LMR Partners’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-211,900
Closed -$51.5M – 1260
2024
Q2 		$51.5M Buy
211,900
+112,700
+114% +$17.8M 0.43% 37
2024
Q1 		$14.8M Buy
99,200
+98,900
+32,967% +$16.5M 0.15% 139
2023
Q4 		$57.4K Hold
300
– – ﹤0.01% 791
2023
Q3 		$53.1K Hold
300
– – ﹤0.01% 726
2023
Q2 		$57K Buy
+300
New +$59.5K ﹤0.01% 654

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LMR Partners's ALNY Position: Q1 2026 in Review

LMR Partners increased its Alnylam Pharmaceuticals (ALNY) stake by 26% in Q1 2026, buying an estimated $5.32M and bringing the position to 74,661 shares worth $24.7M. The position accounts for 0.05% of the portfolio, ranked #181.

LMR Partners first reported a position in ALNY in Q1 2015 and has held it in 18 quarters since. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • LMR Partners held 74,661 shares of Alnylam Pharmaceuticals worth $24.7M as of Q1 2026.
  • LMR Partners bought 15,639 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $5.32M.
  • Alnylam Pharmaceuticals made up 0.05% of LMR Partners's portfolio in Q1 2026, its #181 holding.
  • LMR Partners first reported a position in Alnylam Pharmaceuticals in Q1 2015 and has held it in 18 quarters since.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on LMR Partners's 13F filing for Q1 2026, filed 15 May 2026.